Overview
February 6-8, 2023
DIA's Global Pharmacovigilance and Risk Management Strategies Conference was developed by recognized experts from the biopharmaceutical industry and global regulatory agencies. This conference provides the background, context, and opportunities to discuss current challenges alongside fresh problem-solving strategies that matter most to professionals working in the field.
While we develop our 2023 Agenda, please take a look at the 2022 final agenda.
Program Committee
-
Jeremy Jokinen, PhD, MS • Vice President and Head, Global Risk Management & International Patient Safety
Bristol-Myers Squibb Company, United States -
Annette S. Williams, MBA, RPh • Vice President, Pharmacovigilance
IQVIA, United States -
James Buchanan, PharmD • President
Covilance LLC, United States -
Barbara Hendrickson, MD • Immunology Therapeutic Area Head, Pharmacovigilance and Patient Safety
AbbVie, Inc., United States -
Mamiko Kasho • Executive Director, Global PV Management Dept., Global Safety HQs
Eisai Co., Ltd., Japan -
Susan Kindig, JD, MD • Executive Director, Medical & Drug Safety
Halozyme, United States -
Jamie Ridley Klucken, PharmD, MBA, RPh • Safety Evaluator, Division of Pharmacovigilance, OSE, CDER
FDA, United States -
Mengchun Li, MD, MPA • Director, Phamacovigilance
Global Alliance For TB Drug Development, United States -
Sarah Vaughan • Head of Vigilance Development
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Jo Wyeth, PharmD • Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States
Contact us
Registration Questions?
Additional Information
Live Meeting PoliciesSign up to Learn More about DIA 2023 Spring Events!
Discover DIA’s Live In-Person Events